Stockreport

Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans [Yahoo! Finance]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF See our latest analysis for Exelixis. The recent zanzalintinib readout and upcoming STELLAR-316 trial headlines arrive after a 15.73% 90 day share price return and a [Read more]